Android app on Google Play

RTI Biologics (RTIX) Cuts FY10 Outlook

September 7, 2010 4:04 PM EDT Send to a Friend
RTI Biologics (Nasdaq: RTIX) lowers its FY10 EPS guidance from 15-17c to 10-12c and its sales guidance from $174.5-$177.5 million to $165-$168 million. The Street is currently looking for EPS of 11c on sales of $168.09 million.

The guidance comes amid a distribution pact with Zimmer Dental.




You May Also Be Interested In


Related Categories

Corporate News, Guidance

Add Your Comment